Germinal center (GC) B cells at viral replication sites acquire specificity to poorly immunogenic but conserved influenza hemagglutinin (HA) epitopes. Here, high-throughput epitope mapping of local GC B cells is used to identify conserved HA epitope selecting cross-reactive antibodies that mediate heterosubtypic protection. A distinct feature of this epitope is an occlusion in the naive trimeric HA structure that is exposed in the post-fusion HA structure to occur under low pH conditions during viral replication. Importantly, systemic immunization by the post-fusion HA antigen results in GC B cells targeting the occluded epitope, and induces a class of protective antibodies that have cross-group specificity and afford protection independent of virus neutralization activity. Furthermore, this class of broadly protective antibodies develops at late time points and persists. Our results identify a class of crossprotective antibodies that are selected at the viral replication site, and provide insights into vaccine strategies using the occluded epitope.
V iruses have acquired several mechanisms to evade antibody surveillance as a result of the host/pathogen coevolution, one of which is the acquisition of escape mutations. The counteraction of humoral responses against the escape mutations is to acquire sufficient breadth of antibody specificity to include escape variants and to preserve crossreactive antibody production in long-lived memory compartments (memory B cells and long-lived plasma cells) 1 . Antibody breadth or cross-reactivity is achieved by two different pathways: germline-encoded cross-reactivity for variable viral epitopes or somatic evolution in germinal centers (GCs) for conserved viral epitopes 2 .
Previous observations of an early, GC-independent pathway for recruiting germline-encoded antibodies into the memory compartment led to a proposal that low-affinity/cross-reactive B cells act to increase the breadth of humoral protection [3] [4] [5] . This early, germline cross-reactivity is associated with B cell antigen receptor (BCR)-mediated recognition of variable epitopes with low affinity and supported by the intriguing findings of McGargill's group showing that limiting the generation of highly specific IgG B cells by rapamycin treatment enhanced the breadth of protective antibody responses to influenza 6 .
Protective cross-reactivity is also acquired by targeting conserved viral epitopes that are often immunosubdominant and poorly immunogenic. This process requires the improvement of BCR affinity and specificity through V(D)J mutation and selection within GCs 7 . Extensive analyses of HIV broadly neutralizing antibodies (bNAbs) has highlighted the requirement for extraordinary frequencies of V(D)J mutations and repeated rounds of selection to acquire the requisite affinity/specificity for conserved, immunosubdominant neutralizing epitopes 8 . Likewise, influenza bNAbs that target the hemagglutinin (HA) conserved epitopes acquire the affinity/specificity through the accumulation of V(D)J mutations [9] [10] [11] , albeit to a lesser extent than HIV bNAbs. Thus, V(D)J mutations and selection during the GC pathway fine-tune the specificity and affinity of the antibodies to conserved influenza epitopes. However, GC selection for conserved epitopes appear to be less robust or competitive than that for immunodominant and variable epitopes. The mechanisms for this dichotomy remain elusive and constitute a key issue for developing cross-protective vaccines against rapidly mutating viruses.
By monitoring B cell responses targeting conserved HA epitopes in mice, we previously demonstrated that influenza virus infection induces ectopic formation of lung GCs at the viral replication site, where cross-reactive B cells are selected at increased frequencies 12 . This result prompted us to identify the conserved epitopes that are utilized as selecting antigens and the mechanism of their enhanced immunogenicity. Here, we apply a single cell culture method that allows high-throughput analysis of B cell epitopes in humans and mice 13, 14 . We identify long alpha helix (LAH) epitopes in the HA2 stem regions, which are normally occluded in native HA form, as the selecting epitope for cross-reactive B cells in local GCs. Moreover, we demonstrate that post-fusion HA antigen exposes the LAH epitope to increase its antigenicity and serves as the selecting antigen for the LAHbinding B cells; the consequence of these events is robust and durable elicitation of cross-protective LAH IgG. Thus, GC B cells at viral replication site utilize antigenic plasticity for guiding the specificity to occluded epitopes that potentially include virus vulnerable sites.
Results
Single B cell cultures validate specificity of GC B cells. Using two rHA probes of the same H3 subtype (X31 and A/Uruguay/ 716/07), we detected strain-specific (X31 single positive) and cross-reactive (X31/Urg double positive) GC B cells from the lungs of X31-infected mice, as previously described (Fig. 1a) 12 . The specificity of our staining procedure was thoroughly validated using mouse B cells from naive mice and those from BCRknock-in mice to an unrelated hapten antigen 12 . In addition, we confirmed the antigen specificity of identified GC B cells using single-cell Nojima cultures 13 .
In Nojima cultures, lung GC B cells had lower cloning efficiencies than did phenotypically similar GC B cells from secondary lymphoid tissues 13 (Supplementary Table 1 ), perhaps the consequence of the harsher conditions necessary for the recovery of B cells from lung tissue. We analyzed HA-binding frequencies of the clonal IgGs secreted by strain-specific (69 clones) and cross-reactive (191 clones) GC B cells (Fig. 1a ). The concordance of specificity by flow cytometry and clonal IgG binding was high; 83% (57/69) strain-specific GC clones secreted IgG reactive with only X31 HA and 85% (163/191) of crossreactive clones exhibited the appropriate dual reactivity. We speculate that these specific HA-binding ratios underestimate the actual ratios, because low affinity, soluble antibody may be undetectable by ELISA, even though the membrane-bound form can be detected by flow cytometry using antigen probes 15 . Thus, our previous data and Nojima culture data in this study validate the specificity of our HA probes to identify strain-specific and cross-reactive GC B cells.
LAH is a selecting epitope of cross-reactive GC B cells. Next, we investigated by two independent approaches, which conserved epitopes act to select cross-reactive GC B cells. First, we used the clonal IgGs from single-cell Nojima culture supernatants for epitope mapping, an approach that allows high-throughput analysis of B cell specificity and avidity 13 . Second, we masked the identified epitopes by injecting specific mAb into mice 16 and assessed how significantly the epitopes contribute to the selection in vivo.
We screened the clonal IgGs secreted by cross-reactive lung GC B cells and found that 61% (100/163) bound a synthesized peptide encompassing long alpha helix (LAH) in HA2 ( Fig. 1b) 17 . In contrast, only two GC B cell clones (1.2%, 2/163) bound headonly HA proteins 14 . Epitopes recognized by the remaining crossreactive GC B-cell clones (36.8%, 60/163) remain to be identified and characterized in greater details.
An important class of broadly neutralizing HA antibodies recognize conformational stem epitopes, hereafter denoted as "conformational stem (CS)" antibodies. We selected five, well characterized CS mAbs (FI6, MEDI8852, 16.a.26, 31.a.83, and 56. a.09) [18] [19] [20] , and assessed their binding to full length rHA. Among these five CS mAbs, we found MEDI8852 to most effectively and specifically compete the other CS mAbs for the binding ( Supplementary Fig. 1 ). We chose, therefore, to identify potential CS antibodies among the cross-reactive clonal IgGs by competition with MEDI8852. Only one (1/163; 0.6%) clonal IgG was effectively competed by MEDI8852 and neither bound the LAH peptide nor HA head-only protein ( Supplementary Fig. 1 ). Summarizing the epitope analysis of HA-binding IgG antibodies from cross-reactive GC B cells, we found 61% to be LAH binders, 1.2% to bind the HA head, 0.6% reactive with a CS epitope; 37% of the GC clonal IgGs were not mapped to known epitopes in our screen and were negative for the three parameters tested.
To confirm the dominancy of LAH epitope among crossreactive GC B cells, we masked the LAH epitope by injecting mouse LAH mAb (clone mLAH1) into X31-infected mice. We used mAbs with poorly sialylated Fc to avoid Fc-mediated, immune modulation as previously described ( Supplementary  Fig. 2) 21, 22 . Mice were treated with mLAH1 mAb at day 20 after infection, which was the time point when GC B cell numbers plateaued 12 . In support of the epitope mapping data, mLAH1 selectively reduced the number of cross-reactive GC B cells, but it did not affect the numbers of strain-specific GC B cells ( Fig. 1c, d) . In contrast, passive administration of X31 strain-specific mAb, 1E11, had negligible effects on either GC B cell subset, suggesting that the 1E11 epitope was minor among the hypervariable epitopes for strain-specific GC B cells. Thus, the in vivo epitope masking by antibody infusion confirmed that LAH is the major epitope for selecting cross-reactive GC B cells at the site of viral replication. ARTICLE LAH antibodies provide heterosubtypic protection. The LAH amino acid sequences exhibit about 60% homology between H3 and H7 HA subtypes within group 2, but the similarity decreases slightly, to around 50%, between H3 and group 1 HA subtypes (H1 and H5). To address the heterosubtypic reactivity of H3 LAH-binding antibodies, we examined the reactivity of clonal IgGs from individual Nojima cultures against H7 (intra-group) and H1 and H5 (inter-group) HA proteins ( Fig. 1e ). About one quarter of H3 LAH-binding IgGs also bound the H7 subtype, but fewer recognized H5 (16%) and H1 (3%) proteins. LAH was originally identified as the epitope of mouse crossreactive mAb that reactive to drifted H3 but not to H1 HAs 23 . We randomly selected five LAH-binding B cell clones to made recombinant LAH IgG for testing virus neutralizing activity in vitro using homologous X31 as the challenge virus. For reference, we used MEDI8852 and FI6 as representative CS antibodies, which have highly potent, broadly neutralizing activity 18 . Indeed, both CS mAbs showed H3 virus neutralizing activity at 1.6 μg per mL (MEDI8852) and 3.1 μg per mL (FI6), whereas five LAH mAbs did not show any neutralizing activity up to 50 μg per mL under the same condition ( Supplementary Fig. 3 ).
Despite the lack of virus-neutralizing activity under in vitro, there is accumulating evidence for protection provided by nonneutralizing HA mAbs in vivo 24, 25 . Therefore, the protective ability of representative LAH mAbs (mLAH1 and mLAH2) of the IgG2a subclass was evaluated in X31-infected mice. Prophylactic treatment with LAH mAbs provided significant protection against lethal infection by X31 based on loss of body weight and survival ( Fig. 1f) ; however, the same LAH IgG2a, bearing N297A mutation, partially reduced the protective function in the same challenge experiment. Since the N297A mutation reduces IgG binding to FcγR 26 , non-neutralizing LAH IgGs appear to provide protection through Fc-mediated effector functions, similarly to the protection provided by CS IgGs 27 , although the levels of Fc dependence are variable among LAH mAb clones. Heterosubtypic protection against H7N9 infection was also observed by the prophylactic treatment of LAH mAbs ( Fig. 1g ). Together, H3 LAH-binding IgGs are non-neutralizing but broadly protective antibodies, the activity partly dependent on Fc-mediated effector functions.
LAH-binding memory B cells are present in human.
Owing to past infection and/or vaccination histories, almost all healthy adults have pre-existing memory B cells against influenza HA, which significantly affect the recall antibody responses to future infection and vaccination 28 . It is therefore important to know the frequency of the LAH-binding B cells in the human memory compartment. From the peripheral blood mononuclear cells of seronegative donors (hemagglutination inhibition titers were < 40), we identified cross-reactive B cells from human peripheral blood mononuclear cells using a similar, but slightly different, strategy for mouse B cells. First, we used HA probes from a recent H3N2 vaccine strain, A/Victoria/361/2011, because Vic HAbinding memory B cells are considered to be more abundantly present than those against X31 (reassortant virus bearing HA of 1968 strain) and Urg (isolate from 2007) HAs. Second, we collected Vic HA-binding B cells as double positive cells for Vic HA probes that are labeled by different fluorochromes to reduce contamination by unspecific binders. A similar approach has been proven to reduce the contamination of fluorochromebinding B cells, a significant problem in humans 29 .
We observed that about 40% of the Victoria HA-binding IgG + memory B cells were cross-reactive to X31 HA ( Fig. 2a ). Single cell cultures confirmed that 75% IgG-secreting clones were HAbinding (Supplementary Table 2 ). Epitopes of cross-reactive IgG + memory B cells were mapped using the culture supernatants 14 and LAH binders were identified from 21% clones ( Fig. 2b) . LAH binders were present from all 6 donors (8.8 to 48.6%), showing the multi-donor presentation of this population ( Fig. 2b and Supplementary Table 3 ). The frequency of LAH binders was lower than that from mouse GC B cells (61%), at least in part because MEDI8852 competitors (CS binding) were abundant in human memory B cells (26%) ( Fig. 2b and Supplementary Table 2 ). We also noticed that 37% of the crossreactive clones recognized head-only HA proteins, consistent with recent publications in which substantial fraction of the cross-reactive memory B cells/antibodies were head reactive in humans 14, 24 .
Breadth of specificity to heterosubtypic HAs was examined in H3 LAH-binding clones in parallel to CS-binding clones that are paradigmatic of broadly neutralizing HA mAbs ( Fig. 2c, d) . Notably, the majority (83%) of human LAH-binding clones were broadly reactive to H7 and about one third of clones were even bound to H1 and H5 HAs (Fig. 2c ). CS-binding clones included broadly reactive clones to H7, H1, and H5 as expected, but the frequencies and the levels of binding on average were lower than those of LAH-binding clones (Fig. 2d ).
The functional properties of LAH-and CS-binding mAbs derived from human memory B cells were assessed by in vitro virus neutralization assay and in vivo protection assay using X31 virus. Consistent with previous findings from mouse LAH mAbs, human LAH-binding mAbs (n = 4), regardless of the levels of broad reactivity, did not show detectable virus neutralizing activity to X31 in vitro ( > 50 μg per mL), whereas the CS-binding mAbs neutralized with detectable concentration (7.2 ± 5.1 μg per mL, n = 5) ( Supplementary Fig. 3 ). Despite the lack of neutralizing activity in vitro, LAH-binding mAbs provided levels of protection similar to those provided by control CS-binding mAbs in vivo at < 5 mg per kg ( Fig. 2e ). Moreover, LAH-binding mAbs afforded the heterosubtypic protection against lethal infections by avian H7N9 virus strain ( Fig. 2f ). Taken together, Fig. 1 LAH is a selecting epitope for cross-reactive GC B cells at viral replication site. a X31 HA-binding GC B cells in the lungs were recovered from X31infected BALB/c mice at day 20 after infection and separated into strain-specific (blue) and cross-reactive (red) cells. Antigen specificity of both populations were evaluated by using mAbs in culture supernatants of single cell cultures. b High-throughput epitope mapping analysis was applied to the cross-reactive GC B cells (X31/Urg HA binders) in the lungs. The data from pooled 36 mice is shown. c Cross-reactive GC B cells were enumerated in the lungs 5 days after the injection of LAH-binding IgG1 (mLAH1), head-binding IgG1 (1E11), and non-binding IgG1 (NSP2). d The number of strain-specific and cross-reactive GC B cells were determined by flow cytometry 5 days after antibody treatment. Each circle represents the result from an individual mouse. The combined data from two independent experiments are shown. e Heterosubtypic reactivity of H3 LAH-binding clones was evaluated by ELISA using rHA as coating antigens. H3; X31, H7; A/Anhui/1/2013, H1; A/Narita/ these observations demonstrate that LAH-binding IgG antibodies in humans are broadly protective in vivo, independent of in vitro virus neutralizing activity.
Conserved epitopes are occluded in native trimeric HA. HA proteins lacking transmembrane domain (ΔTM HA) generates various HA forms including monomeric form 30 . Since we used the ΔTM HA as the probe to detect the HA-binding B cells, the usage of non-native HA as probe might be one technical reason for the successful isolation of LAH-binding B cells. Consequently, we compared B cell access to the HA epitopes present on the ΔTM HA and trimeric HA. For this purpose, we recovered GC B cells from virus-infected mice and analyzed the binding ability of BCRs to both HAs ( Fig. 3a and Supplementary Fig. 4 ). More than half of the splenic GC B cells were categorized into double binders with the binding capabilities comparable to both HA antigens. In contrast, the ratios of double binders were significantly reduced in the mediastinal lymph node and lung GC B cells; reciprocally, ΔTM HA-specific populations increased up to 80% in the lungs where viral replication occurred. Together, these results suggest that lung GC B cells were predominantly selected by the epitopes, which were occluded in native trimeric HA, but were exposed in non-native HA that includes monomeric form.
To assess the requirement of viral replication for the exposure of occluded epitopes, we intranasally inoculated live or inactivated viruses into the mice and induced lung GC B cells by the viruses with or without replication. LAH antibodies bound to inactivated virus, but LAH epitope was apparently exposed at lower effective density than epitopes for strain-specific and CSbinding antibodies ( Supplementary Fig. 5 ). We detected HAbinding lung GC B cells after intranasal injection of inactivated X31 viruses, albeit at lower frequencies than after live virus infection (525.5 ± 512.0 per lung from live virus versus 96.3 ± 74.2 per lung from inactivated virus, n > 10). Among the X31 HAbinding GC B cells gated, 37% on average were cross-reactive after live virus inoculation, but only 4% of GC B cells were double binders in mice that received inactivated viruses (Fig. 3b, c) . These results demonstrate that the exposure of occluded epitopes is dependent on virus replication.
LAH epitope is exposed in post-fusion HA. During the viral replication process, influenza viruses convert the native HA into a post-fusion HA form under the acidic conditions within endosome 31, 32 . Importantly, the structure of post-fusion HA antigen exposes LAH epitope toward membrane-distal regions, likely reducing the steric hindrance for antibody access that occurs in native, pre-fusion HA 31, 32 . Therefore, we tested whether post-fusion HA antigen is the selecting antigen at the site of viral replication through three approaches.
First, we assessed the binding of the mAb panel toward native and post-fusion HA antigen by ELISA and calculated the avidity index, as previously described (Fig. 4a) 13 . Strain-specific mAbs bound equally to both forms of the HA antigens, an observation that supports the conservation of strain-specific epitopes in postfusion HA created by low pH treatment. As expected, post-fusion HA antigen modified the native conformation of CS epitopes and reduced binding by CS mAbs. On the contrary, the binding of LAH-binding mAbs to post-fusion HA antigen was substantially better than to native HA.
Second, we examined the avidity index of a large panel of cross-reactive mAbs from mouse Nojima cultures (Fig. 4b) . The comparative analysis of avidity index toward native and postfusion HA antigens supported that majority of the cross-reactive antibodies, irrespective of LAH-and non-LAH binding, bound the post-fusion HA antigen more avidly than to the native HA antigen. These binding data using soluble form of mAbs demonstrate that the LAH epitope, along with other occluded epitopes, is exposed in post-fusion HA antigen.
Membrane-bound BCRs on the surface of B cells are more susceptible to HA structural constrains than antibodies in soluble form, owing to restricted orientation for HA binding. As the third approach, we assessed the binding ability of membrane-bound BCRs on GC B cells (strain-specific and cross-reactive, separately) toward post-fusion versus native, pre-fusion HA antigens by flow cytometry (Fig. 4c ). Strain-specific GC B cells from all organs bound equally to both forms of HA antigens (Fig. 4d ), supporting again that strain-specific epitopes were relatively conserved in post-fusion HA antigen created by our condition. In contrast, cross-reactive GC B cells bound better to post-fusion HA antigen relative to native HA antigen, and the differential binding was (Fig. 4e ). The increased access of cross-reactive GC B cells toward post-fusion HA antigen further strengthens our idea that the selection for lung GC B cells is mediated by post-fusion HA antigen that exposes LAH epitope along with strain-specific epitopes. This also accounts for the equivalent selection of strain-specific and cross-reactive GC B cells in the lungs.
Post-fusion HA antigen elicits LAH-binding GC B cells. It is technically challenging to isolate the selecting antigens from local GCs and compare the antigenic structure with that of post-fusion HA antigen; therefore, we decided to compare the antibody epitope profiles selected by both antigens. We have already completed the epitope profile from local GC B cells in Fig. 1b , so that we determined the antibody epitope profile in the mice that received the post-fusion HA antigen as an immunogen. HAbinding, splenic GC B cells elicited by the post-fusion HA immunogen were quantitatively comparable to those by the native HA immunogen beyond day 14 after immunization ( Supplementary Fig. 6 ), confirming the equivalent immunogenicity of post-fusion HA antigen. In contrast, the ratios of crossreactive GC B cells elicited by the two immunogens were totally different; about half of GC B cells elicited by post-fusion HA antigen were double binders as we had previously observed in the local GC B cells ( Fig. 1) 12 , whereas such cross-reactive GC B cells was below the detection limit after immunization with native, pre-fusion HA antigen (Fig. 5a ). Then, cross-reactive GC B cells ARTICLE were applied to Nojima cultures for determining the contribution of LAH epitope as the selecting epitopes ( Fig. 5b and Supplementary Table 4 ). Through the analysis of 319 cross-reactive GC B cell clones, LAH-binding antibodies were dominant (52%), and CS-binding antibodies and head-binding antibodies were minor (8 and 4%), which reproduces the epitope profile in infectioninduced lung GC B cells (Fig. 1b) . Thus, the comparable antigenic properties along with the improved access by cross-reactive B cells/antibodies support that post-fusion HA antigen is the selecting antigen in local GCs and eliciting LAH-binding GC B cells at the viral replication site. GC responses produce at least two types of long-lived B cells: memory B cells and long-lived plasma cells. Analogous to GC responses, the numbers of HA-binding memory B cells were comparable in the mice receiving post-fusion and native HA antigens. However, surprisingly, cross-reactive memory B cells were less frequent than the equivalents in GC B cells up to day 100 after immunization (Fig. 5c ). When we extended the analysis to long-lasting serum IgG titers produced by long-lived plasma cells, we noticed that post-fusion HA immunogen robustly induced IgG antibodies that were cross-reactive to drifted Urg HA and LAH peptide ( Supplementary Fig. 6 ). This led to increased frequencies of Urg HA-binding IgG antibodies in the serum, reaching levels comparable with that of GC B cells (Fig.  5d) . These data suggest that the altered antigenicity of post-fusion HA antigen prompted the recruitment of cross-reactive B cells into plasma cells rather than into memory B cells. Moreover, we detected low levels of neutralizing activity against drifted Urg virus in day 14 serum (Fig. 5e ), but the activity was significantly reduced by day 28 after immunization, even though Urg HAbinding antibody titers were stable or rather enhanced from days 14 to 28 ( Supplementary Fig. 6 ). These data suggest that antibodies neutralizing drifted viruses promptly emerge in the early time points, but they gradually decline with time. In stark contrast to the transient elevation of the cross-neutralizing antibodies, LAH antibodies were minorly represented within the drifted HA-binding IgG fraction in the early time points, but their ratios increased toward day 42, and the numbers were maintained up to day 100 (Fig. 5f ). Thus, post-fusion vaccination elicited two waves of cross-reactive antibody responses that were previously unappreciated; prompt and transient induction of neutralizing antibodies in the first wave, and gradual and persistent induction of non-neutralizing LAH antibodies in the second wave.
Post-fusion HA antigen elicits cross-protective antibodies. Upon boosting, post-fusion HA antigen induced LAH-binding IgG 7-fold higher than native HA antigen, regardless of comparable HAbinding IgG titers between the two types of HA antigens (Fig. 6a ).
Using the immune serum, we assessed the functions of polyclonal antibodies elicited by post-fusion HA antigen. First, virus neutralizing activity of the immune serum was examined against the homologous (X31) and heterologous (Guizhou) H3N2 viruses (Fig.  6b ), both of which were pathogenic to BALB/c mice and applicable to in vivo challenge experiments in comparison to in vitro assay. The immune serum elicited by both HA antigens exhibited virus neutralizing activity to homologous virus, which was again consistent with the idea that strain-specific epitopes were relatively wellconserved in post-fusion HA antigen. In contrast, neither of the serum exhibited neutralizing activity against heterologous virus.
Therefore, cross-neutralizing antibodies were neither boosted nor maintained after boosting by post-fusion HA antigen. We also performed passive transfer experiments to assess in vivo protective function of the same immune serum. It is important to mention that HA-binding antibodies in the immune serum were predominantly IgG1 subclass, which is less protective than IgG2 subclass owing to low affinity binding to activating FcγRs 27 . Moreover, we infused the immune serum containing HA-binding IgG antibodies at < 1 mg per kg body weight of recipient mice. Even under such suboptimal conditions, the immune serum from post-fusion immune mice provided partial but significant protection against the lethal infection by the heterologous strain (Fig. 6c ), whereas the immune serum from native HA-immune mice did not provide any protection at all. Thus, post-fusion HA antigen can induce cross-protective IgG antibodies in the serum of vaccinated mice.
To clarify antigenic properties of post-fusion HA antigen on human memory B cells, we used human PBMC-transplanted immunocompromised NOD/SCID/Jak3 -/-(NOJ) mice under the conditions where human memory B cells can be restimulated by influenza vaccines 33 . The NOJ mice produced comparable amounts of HA-binding human IgG responses after immunization with two forms of HA antigens (Fig. 6d) ; however, a majority of human IgG responses were found to recognize LAH epitope after immunization with post-fusion HA antigen only, but not with native HA antigen. Thus, post-fusion HA antigen is able to effectively boost LAH-binding IgG antibodies from human memory lymphocytes, implying the potential application of this immunogen as a vaccine for human use. 
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Discussion
Natural influenza virus infections broaden antibody specificity and afford cross-protection against mutant viruses at local infection sites 34, 35 . We have found local GCs, ectopically formed at the site of viral replication, as the key induction sites of crossreactive antibodies that target conserved epitopes 12 . With the introduction of high-throughput single-cell cultures, we identified the LAH epitope as a dominant selecting determinant that is occluded in native HA trimer but exposed in the post-fusion HA antigen as immunogenic epitopes. The antigenic properties of post-fusion HA antigen and its elevated accessibility by crossreactive B cells/antibodies support the post-fusion HA antigen as the major selecting antigen in local GCs. We have demonstrated a unique property of GC selection at sites of infection that has significant functional relevance for eliciting cross-protective antibodies.
Recent studies revealed the heterogeneity of GC selection that is proposed to arise, at least partly, from epitope modification of selecting antigens in vivo 13, 36 . The post-fusion HA antigen provides the example of a non-native antigen, which promotes B cell selection toward conserved epitopes that are occluded, and poorly immunogenic, in the native antigen. Post-fusion HA forms emerges under the acidic conditions (pH 5.0) in endosomes during viral replication. This location raises the question of how the endosomal HA antigen can act as selecting antigen for GC B cells and displayed by follicular dendritic cells (FDCs). In this context, at least two possibilities can be envisaged. First, many influenza-infected cells die; the death process may release the intracellular viral antigens for trapping by FDCs. Second, extensive inflammatory reactions against pathogens may generate extracellular acidification, creating post-fusion HA proteins outside of the cell 37, 38 . In either events, we think it is important to note that several protective human HA mAbs recognize occluded epitopes that are exposed in the low pH HA conformation 25, 39 . These observations strongly support that the selection by postfusion HA antigen is not unique to our experimental conditions but rather a commonly observed event in both humans and mice.
We dissected two types of cross-reactive antibodies in temporally separated phases using the mice immunized with post-fusion HA antigen. Cross-neutralizing antibodies arise during the early time points, and non-neutralizing but cross-protective antibodies start to emerge later in the circulation concordantly to the decline of neutralizing antibodies (Fig. 5 ). We speculate that the early wave of neutralizing antibody development shown in this study represents germline-encoded cross-reactivity through the GCindependent pathway that can be enhanced by rapamycinmediated mTOR inhibition and GC suppression 6 . In contrast to the previous finding under GC-suppressed condition 6 , the early, neutralizing antibody responses declined over time, suggesting that GC-derived antibodies in the late time points replace the preexisting neutralizing antibodies by competition. In line with this, H5N1 vaccinee produced cross-reactive (H5/H1) memory B cells against stem domains, but the memory B cells were found to be less persistent than those against head domains in clinical study 40 . Thus, it would be interesting to examine whether neutralizing CS antibodies are less competitive with other HA antibodies in animal model.
An important question remains elusive how non-neutralizing LAH antibodies provide broad protection in vivo. The study using IgG mutant (N297A) in Fig. 1f supports the involvement of Fc-mediated protection, although the levels of Fc dependence are variable among LAH mAb clones. Of note, the similar heterogeneity on Fc dependence was previously shown in human protective IgGs against occluded epitopes that are exposed in low pH-induced HA conformation 25, 39 ; some of them require Fcmediated mechanisms for maximizing the protective capacities, but others do not. These data including ours in this study suggest that Fc-mediated pathway contributes to the protection within the limited ranges of antibody dosage and/or their binding properties, such as affinity and epitopes. Once these parameters are under the appropriate conditions, Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and/or complementdependent cytotoxicity may operate and remove the infected cells for viral clearance 39, [41] [42] [43] . What kind of conditions are required for activating the individual Fc-mediated mechanisms remain to be addressed.
Previous work, including our own, have utilized mouse infection models to demonstrate humoral protection by Fc-dependent pathways 25, 27, [44] [45] [46] . The use of mice, despite the differences in pathophysiology of influenza infection compared to humans, is critical because little information exists on IgG subclasses and FcγR activity, distribution and signaling in more typical animal models (e.g., ferret). Indeed, absent this information, any Fcmediated protection-or lack of it-activity by passively transferred IgGs is difficult to interpret. In this context, we note that a recent clinical study observed a significant correlation of protection with several types of pre-existing antibodies 47 not only neutralizing HA antibodies but also poorly neutralizing HA and NA antibodies that require Fc-mediated mechanisms to maximize the protection in mice 27, 46 . Thus, the limited clinical data suggests the possible relevance of Fc-mediated protection during natural influenza infection in humans.
Elicitation of transient neutralizing antibodies and persistent non-neutralizing antibodies by post-fusion HA antigen provides several important implications for future strategies of universal influenza vaccine. Cross-neutralizing antibodies are important and promising targets that need to be elicited robustly and durably by vaccination. However, the factors hampering the durable elicitation, such as the polyreactivity of CS antibodies 28, 48 , need to be further evaluated. Future comparative studies between neutralizing CS and non-neutralizing LAH antibodies might reveal the functional compartmentalization of these two classes of crossprotective antibodies, which would be required for the rational design of a universal influenza vaccine that potentiates broad protection through multiple points of action.
Methods
Virus and vaccine. IVR-165 (A/Victoria/361/2011; H3N2) was provided by Commonwealth Serum Laboratories. A/Anhui/1/2013 (H7N9) virus was provided by China CDC. All viruses including X31 (H3N2), A/Uruguay/716/07 (H3N2), A/ Narita/1/09 (H1N1), and A/Guizhou/54/89 (H3N2) strains were propagated in embryonated chicken eggs and purified by a sucrose gradient (10-50%) ultracentrifugation. For inactivation, purified viruses were treated with 0.05% formalin at 4°C for a week. To produce the HA-split vaccines, purified live viruses were suspended in 0.1% Tween80 and mixed with an equal volume of ether. After stirring, the mixture was centrifuged to separate the aqueous and ether phases, and the ether phase was discarded. After several rounds of extraction, the remaining aqueous phase was collected as the HA-split vaccine. For post-fusion HA-split vaccine, HA-split vaccines were mixed with 0.15 M citrate buffer and treated with acidic buffer (pH 5.0) for 30 min to cause irreversible transition into post-fusion form 32 , and then neutralized by adding 1 M Tris-HCl buffer pH 8.0. HA-split vaccines were enriched by ultrafiltration (Sartorius) and then treated with formalin at 4°C for a week before use.
Mice. BALB/c mice were purchased from Japan SLC. NOD/SCID/JAK3 -/mice were kindly provided by Dr. S. Okada (Kumamoto University). All mice were maintained under SPF condition and used at 7-12 weeks of ages.
Virus infection and challenge experiments. BALB/c mice were anesthetized by i. p. (intraperitoneal) injection with sodium pentobarbital and then i.n. (intranasal) infected with X31 virus or Narita virus at a dose of 0.2 × LD50 in a volume of 20 μL. Some groups of the mice were i.p. treated with 100 μg of mAb or 200 μl of immune serum more than 3 h before being challenged by either X31 (5 × LD50), A/Guizhou/54/89 (5 × LD50), or A/Anhui/1/2013 (1 × LD50). All mice were monitored daily for survival and body weight loss until 14 days after infection. The humane endpoint was set at 25% body weight loss relative to the initial body weight at the time of infection.
Immunization. BALB/c mice were i.p. immunized with native-or post-fusion HAsplit antigens (10 μg) along with the adjuvant AddaVax (InvivoGen), and boosted with the same dose of antigens without AddaVax at day 28 after immunization. Sera were collected at day 14 after boosting. In some experiments, mice received i.n. administration of inactivated viruses twice at 28-day intervals, and the lungs were recovered at day 7 after boosting for flow cytometric analysis.
Statistics. Statistical analyses were performed with a two-tailed Mann-Whitney test or Wilcoxon matched-pairs signed rank test. Statistical significance between the survival rates was determined by Kaplan-Meier survival curves and log-rank test. All statistical analyses were performed using Prism (GraphPad). P-values < 0.05 were considered significant and indicated by asterisks: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Study approval. The studies using human samples were approved by the Institutional Ethics Committee of Human Experimentation and performed in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. All participants provided written informed consent in accordance with the Declaration of Helsinki. Animal procedures were approved by the Animal Ethics Committee of the National Institute of Infectious Diseases, Japan, and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee.
